AlloVir, Inc. (NASDAQ:ALVR – Get Rating) insider Vikas Sinha sold 5,111 shares of the company’s stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $5.08, for a total transaction of $25,963.88. Following the completion of the sale, the insider now owns 1,031,664 shares in the company, valued at approximately $5,240,853.12. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
AlloVir Stock Performance
NASDAQ:ALVR traded down $0.12 on Monday, hitting $5.13. The stock had a trading volume of 151,167 shares, compared to its average volume of 217,905. The stock has a market cap of $477.93 million, a P/E ratio of -1.83 and a beta of 0.87. AlloVir, Inc. has a 1 year low of $3.17 and a 1 year high of $10.29. The firm’s fifty day simple moving average is $6.30 and its two-hundred day simple moving average is $6.94.
AlloVir (NASDAQ:ALVR – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.02. Equities research analysts predict that AlloVir, Inc. will post -2.28 EPS for the current year.
Analysts Set New Price Targets
Institutional Investors Weigh In On AlloVir
Several large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its stake in shares of AlloVir by 33.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,210 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares during the last quarter. Ensign Peak Advisors Inc increased its stake in shares of AlloVir by 27.0% during the 3rd quarter. Ensign Peak Advisors Inc now owns 7,300 shares of the company’s stock worth $58,000 after purchasing an additional 1,550 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of AlloVir by 6.3% during the 3rd quarter. Alliancebernstein L.P. now owns 28,500 shares of the company’s stock worth $225,000 after purchasing an additional 1,700 shares during the last quarter. PDT Partners LLC increased its stake in shares of AlloVir by 10.3% during the 2nd quarter. PDT Partners LLC now owns 33,315 shares of the company’s stock worth $130,000 after purchasing an additional 3,117 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in AlloVir in the 3rd quarter worth approximately $25,000.
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
- Get a free copy of the StockNews.com research report on AlloVir (ALVR)
- Can We Trust The Rally In The S&P 500
- Energy Surge: Four Oil-And-Gas Stocks Setting Up In Bullish Bases
- One ETF Trading Strategy to Beat the Market in 2023
- Is Wayfair Still Way Cheap For Investors?
- When Does Pfizer Become A Bargain?
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.